Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06031337

Enrollment

Registered

2023-09-11

Start date

2023-09-03

Completion date

2023-12-01

Last updated

2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Cancer, Oral Squamous Cell Carcinoma

Brief summary

The study will include patients with oral cancer and healthy controls of both sexes. Subjects having any systemic diseases or other types of cancer will be excluded. All subjects will be selected from Oral Medicine Department, Faculty of Dentistry, Al Ahram Canadian University and Fayoum University. Informed consent will be obtained from all subjects enrolled in this study after explanation of the whole procedure.

Interventions

DIAGNOSTIC_TESTELISA

quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients with oral cancer

Exclusion criteria

* any systemic diseases or other types of cancer will be excluded

Design outcomes

Primary

Measure	Time frame
salivary expression of SOX7	2 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026